Givinostat

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Givinostat
DrugBank Accession Number
DB12645
Background

Givinostat has been used in trials studying the treatment of Polycythemia Vera, Juvenile Idiopathic Arthritis, Duchenne Muscular Dystrophy (DMD), Chronic Myeloproliferative Neoplasms, and Polyarticular Course Juvenile Idiopathic Arthritis.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 421.497
Monoisotopic: 421.200156361
Chemical Formula
C24H27N3O4
Synonyms
  • Givinostat

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcrivastineThe risk or severity of QTc prolongation can be increased when Acrivastine is combined with Givinostat.
AdenosineThe risk or severity of QTc prolongation can be increased when Givinostat is combined with Adenosine.
AjmalineThe risk or severity of QTc prolongation can be increased when Ajmaline is combined with Givinostat.
AlfuzosinThe risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Givinostat.
AlimemazineThe risk or severity of QTc prolongation can be increased when Alimemazine is combined with Givinostat.
AmantadineThe risk or severity of QTc prolongation can be increased when Amantadine is combined with Givinostat.
AmifampridineThe risk or severity of QTc prolongation can be increased when Givinostat is combined with Amifampridine.
AmiodaroneThe risk or severity of QTc prolongation can be increased when Givinostat is combined with Amiodarone.
AmisulprideThe risk or severity of QTc prolongation can be increased when Amisulpride is combined with Givinostat.
AmitriptylineThe risk or severity of QTc prolongation can be increased when Givinostat is combined with Amitriptyline.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phenylcarbamic acid esters. These are ester derivatives of phenylcarbamic acids.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenylcarbamic acid esters
Direct Parent
Phenylcarbamic acid esters
Alternative Parents
Naphthalenes / Benzoic acids and derivatives / Benzoyl derivatives / Aralkylamines / Carbamate esters / Trialkylamines / Organic carbonic acids and derivatives / Hydroxamic acids / Organopnictogen compounds / Organic oxides
show 2 more
Substituents
Amine / Amino acid or derivatives / Aralkylamine / Aromatic homopolycyclic compound / Benzoic acid or derivatives / Benzoyl / Carbamic acid ester / Carbonic acid derivative / Carbonyl group / Carboxylic acid derivative
show 12 more
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
5P60F84FBH
CAS number
497833-27-9
InChI Key
YALNUENQHAQXEA-UHFFFAOYSA-N
InChI
InChI=1S/C24H27N3O4/c1-3-27(4-2)15-17-5-7-21-14-18(6-8-20(21)13-17)16-31-24(29)25-22-11-9-19(10-12-22)23(28)26-30/h5-14,30H,3-4,15-16H2,1-2H3,(H,25,29)(H,26,28)
IUPAC Name
{6-[(diethylamino)methyl]naphthalen-2-yl}methyl N-[4-(hydroxycarbamoyl)phenyl]carbamate
SMILES
CCN(CC)CC1=CC=C2C=C(COC(=O)NC3=CC=C(C=C3)C(=O)NO)C=CC2=C1

References

General References
Not Available
PubChem Compound
9804992
PubChem Substance
347828853
ChemSpider
7980752
BindingDB
50105329
ChEBI
94187
ChEMBL
CHEMBL1213492
ZINC
ZINC000003820616
PDBe Ligand
QCM
Wikipedia
Givinostat
PDB Entries
6uoc

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentDuchenne's Muscular Dystrophy (DMD)1
2Active Not RecruitingTreatmentBecker's Muscular Dystrophy (BMD)1
2Active Not RecruitingTreatmentChronic Myeloproliferative Neoplasms1
2CompletedTreatmentActive Systemic / Onset Juvenile Idiopathic Arthritis1
2CompletedTreatmentMyeloproliferative Disorders (MPD)1
2CompletedTreatmentPolycythemia Vera (PV)1
2TerminatedTreatmentPolyarticular-course Juvenile Idiopathic Arthritis (JIA)1
2, 3Enrolling by InvitationTreatmentDuchenne's Muscular Dystrophy (DMD)1
1CompletedTreatmentDuchenne and Becker Muscular Dystrophy / Polycytemia Vera1
1, 2CompletedTreatmentDuchenne's Muscular Dystrophy (DMD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0052 mg/mLALOGPS
logP4.18ALOGPS
logP3.51ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)9.99ChemAxon
pKa (Strongest Basic)9.35ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area90.9 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity122.49 m3·mol-1ChemAxon
Polarizability47.59 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 23:24 / Updated on February 21, 2021 18:53